{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:39:54Z","timestamp":1791257994142,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272524"],"award-info":[{"award-number":["81272524"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773021"],"award-info":[{"award-number":["81773021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cbi.2023.110740","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T20:48:15Z","timestamp":1696452495000},"page":"110740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells"],"prefix":"10.1016","volume":"385","author":[{"given":"Jian-Lei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Lai","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-322X","authenticated-orcid":false,"given":"Xin-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2023.110740_bib1","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1159\/000358719","article-title":"MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells","volume":"33","author":"Xu","year":"2014","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.cbi.2023.110740_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10549-015-3430-3","article-title":"Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer","volume":"151","author":"Beg","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.cbi.2023.110740_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1758834012475152","article-title":"Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects","volume":"5","author":"Stagg","year":"2013","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.cbi.2023.110740_bib4","doi-asserted-by":"crossref","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23","author":"Andre","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cbi.2023.110740_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1309\/AJCPR11DEAYPTUSL","article-title":"Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer","volume":"141","author":"Dean","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.cbi.2023.110740_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","article-title":"Tenets of PTEN tumor suppression","volume":"133","author":"Salmena","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2023.110740_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/1535-7163.MCT-12-0781","article-title":"Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities","volume":"12","author":"Craig","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2023.110740_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential role for nuclear PTEN in maintaining chromosomal integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2023.110740_bib9","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.4161\/cc.8.14.8947","article-title":"Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair","volume":"8","author":"Gupta","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cbi.2023.110740_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.cbi.2023.110740_bib11","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.18632\/oncotarget.2993","article-title":"PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma","volume":"6","author":"Majuelos-Melguizo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2023.110740_bib12","doi-asserted-by":"crossref","first-page":"32396","DOI":"10.18632\/oncotarget.6136","article-title":"Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition","volume":"6","author":"Middleton","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2023.110740_bib13","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2023.110740_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor","year":"2015","journal-title":"Mol. Cell."},{"key":"10.1016\/j.cbi.2023.110740_bib15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","article-title":"Targeting the replication stress response through synthetic lethal strategies in cancer medicine","volume":"7","author":"Ngoi","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.cbi.2023.110740_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2018.03.005","article-title":"Targeting the replication stress response in cancer","volume":"188","author":"Forment","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2023.110740_bib17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.cbi.2023.110740_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113911","article-title":"Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells","volume":"175","author":"Aubets","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2023.110740_bib19","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cbi.2023.110740_bib20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.cbi.2023.110740_bib21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, A novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2023.110740_bib22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2023.110740_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10549-018-4683-4","article-title":"Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy","volume":"169","author":"Al-Subhi","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.cbi.2023.110740_bib24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.molcel.2006.06.028","article-title":"Mechanistic insights into maintenance of high p53 acetylation by PTEN","volume":"23","author":"Li","year":"2006","journal-title":"Mol. Cell."},{"key":"10.1016\/j.cbi.2023.110740_bib25","doi-asserted-by":"crossref","first-page":"14066","DOI":"10.1074\/jbc.M114.558155","article-title":"Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle","volume":"289","author":"Choi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2023.110740_bib26","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1038\/s41467-021-25346-4","article-title":"RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage","volume":"12","author":"Krais","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cbi.2023.110740_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"Neve","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cbi.2023.110740_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/BD-2010-0307","article-title":"Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer","volume":"32","author":"Chavez","year":"2010","journal-title":"Breast Dis."},{"key":"10.1016\/j.cbi.2023.110740_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920982853","article-title":"ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer","volume":"12","author":"Feng","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cbi.2023.110740_bib30","doi-asserted-by":"crossref","first-page":"10411","DOI":"10.1074\/jbc.M110.210989","article-title":"hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis","volume":"286","author":"Pabla","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2023.110740_bib31","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1074\/jbc.M707568200","article-title":"ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis","volume":"283","author":"Pabla","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2023.110740_bib32","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/sj.emboj.7601446","article-title":"ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling","volume":"25","author":"Stiff","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.cbi.2023.110740_bib33","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1016\/j.celrep.2016.12.031","article-title":"Cancer-specific synthetic lethality between ATR and CHK1 kinase activities","volume":"17","author":"Sanjiv","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.cbi.2023.110740_bib34","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-14-3502","article-title":"Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM","volume":"75","author":"McCabe","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2023.110740_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/JEP.S267383","article-title":"Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy","volume":"13","author":"Tchounwou","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.cbi.2023.110740_bib36","doi-asserted-by":"crossref","first-page":"22932","DOI":"10.1074\/jbc.274.33.22932","article-title":"Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells","volume":"274","author":"Boulares","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2023.110740_bib37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"gammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cbi.2023.110740_bib38","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1038\/onc.2014.276","article-title":"ATR inhibition preferentially targets homologous recombination-deficient tumor cells","volume":"34","author":"Krajewska","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2023.110740_bib39","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.celrep.2019.09.008","article-title":"ATR signaling uncouples the role of RAD51 paralogs in homologous recombination and replication stress response","volume":"29","author":"Saxena","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.cbi.2023.110740_bib40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/sj.onc.1207098","article-title":"Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability","volume":"23","author":"Richardson","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2023.110740_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41416-021-01609-1","article-title":"Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts","volume":"126","author":"Guffanti","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cbi.2023.110740_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cbi.2023.110740_bib43","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1158\/0008-5472.CAN-09-0042","article-title":"Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer","volume":"69","author":"Miller","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2023.110740_bib44","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2023.110740_bib45","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2023.110740_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cbi.2023.110740_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cbi.2023.110740_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.cbi.2023.110740_bib49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4137\/BMI.S39445","article-title":"Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells","volume":"11","author":"Velma","year":"2016","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.cbi.2023.110740_bib50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/mol.59.4.657","article-title":"Is cisplatin-induced cell death always produced by apoptosis?","volume":"59","author":"Gonzalez","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2023.110740_bib51","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1128\/MCB.00447-06","article-title":"Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit","volume":"26","author":"Leung-Pineda","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.cbi.2023.110740_bib52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccr.2005.01.009","article-title":"Lack of PTEN sequesters CHK1 and initiates genetic instability","volume":"7","author":"Puc","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cbi.2023.110740_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125482","article-title":"A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments","volume":"10","author":"Mohni","year":"2015","journal-title":"PLoS One"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723004076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723004076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:52:40Z","timestamp":1777391560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279723004076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":53,"alternative-id":["S0009279723004076"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110740","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110740"}}